Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

The Lancet

Volumn 346, Issue 8967, 1995, Pages 69-74

  Winston, D J ^a   Wirin, D ^a   Shaked, A ^a   Busuttil, R W ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; OKT 3; PLACEBO; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; LIVER BIOPSY; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; THROMBOCYTOPENIA;

EID: 0029065431     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)92110-9     Document Type: Article

References (30)

1. Cytomegalovirus infection after liver transplantation: clinical manifestations and strategies for prevention
2. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies
3. Clinical patterns of cytomegalovirus disease after liver transplantation
4. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial
5. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts
6. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation
7. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation
8. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial
9. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
10. One thousand liver transplants: the lessons learned
11. Evaluation of oral acyclovir
12. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function
13. A prospective randomized trial comparing sequential ganciclovir—high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
14. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir
15. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients
16. Update on oral ganciclovir for CMV reginitis
17. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
18. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis
19. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation
20. The cost impact of cytomegalovirus disease in renal transplant recipients
21. Increased pulmonary superinfections in cardiac-transplant patients undergoing cytomegalovirus infection
22. The prevention of cytomegalovirus disease in renal transplantation
23. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients A randomized trial
24. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants
25. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
26. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation
27. Relationship of the polymerase chain reaction for cytomegalovirus to the development of hepatitis in liver transplant recipients
28. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients
29. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3